Feasibility of the evidence-based cognitive telerehabilitation program ReMind for patients with primary brain tumors

Research output: Contribution to journalArticleScientificpeer-review

28 Downloads (Pure)

Abstract

Many patients with primary brain tumors experience cognitive deficits. Cognitive rehabilitation programs focus on alleviating these deficits, but availability of such programs is limited. Our large randomized controlled trial (RCT) demonstrated positive effects of the cognitive rehabilitation program developed by our group. We converted the program into the iPad-based cognitive rehabilitation program ReMind, to increase its accessibility. The app incorporates psychoeducation, strategy training and retraining. This pilot study in patients with primary brain tumors evaluates the feasibility of the use of the ReMind-app in a clinical (research) setting in terms of accrual, attrition, adherence and patient satisfaction. The intervention commenced 3 months after resective surgery and patients were advised to spend 3 h per week on the program for 10 weeks. Of 28 eligible patients, 15 patients with presumed low-grade glioma or meningioma provided informed consent. Most important reason for decline was that patients (7) experienced no cognitive complaints. Participants completed on average 71% of the strategy training and 76% of the retraining. Some patients evaluated the retraining as too easy. Overall, 85% of the patients evaluated the intervention as “good” or “excellent”. All patients indicated that they would recommend the program to other patients with brain tumors. The ReMind-app is the first evidence-based cognitive telerehabilitation program for adult patients with brain tumors and this pilot study suggests that postoperative cognitive rehabilitation via this app is feasible. Based on patients’ feedback, we have expanded the retraining with more difficult exercises. We will evaluate the efficacy of ReMind in an RCT.
Original languageEnglish
Pages (from-to)523-532
JournalJournal of Neuro-Oncology
Volume137
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Telerehabilitation
Meningioma
Informed Consent
Glioma
Exercise

Keywords

  • CARE
  • CLINICAL-TRIALS
  • CONTROLLED-TRIAL
  • CRITERIA
  • Cognitive rehabilitation
  • DEFICITS
  • DEPRESSION SCALE
  • Glioma
  • HOSPITAL ANXIETY
  • LOW-GRADE GLIOMA
  • Meningioma
  • Neurosurgery
  • REHABILITATION PROGRAM
  • Telerehabilitation
  • eHealth

Cite this

@article{86ae7a789cd243b5b8c139b8802b5028,
title = "Feasibility of the evidence-based cognitive telerehabilitation program ReMind for patients with primary brain tumors",
abstract = "Many patients with primary brain tumors experience cognitive deficits. Cognitive rehabilitation programs focus on alleviating these deficits, but availability of such programs is limited. Our large randomized controlled trial (RCT) demonstrated positive effects of the cognitive rehabilitation program developed by our group. We converted the program into the iPad-based cognitive rehabilitation program ReMind, to increase its accessibility. The app incorporates psychoeducation, strategy training and retraining. This pilot study in patients with primary brain tumors evaluates the feasibility of the use of the ReMind-app in a clinical (research) setting in terms of accrual, attrition, adherence and patient satisfaction. The intervention commenced 3 months after resective surgery and patients were advised to spend 3 h per week on the program for 10 weeks. Of 28 eligible patients, 15 patients with presumed low-grade glioma or meningioma provided informed consent. Most important reason for decline was that patients (7) experienced no cognitive complaints. Participants completed on average 71{\%} of the strategy training and 76{\%} of the retraining. Some patients evaluated the retraining as too easy. Overall, 85{\%} of the patients evaluated the intervention as “good” or “excellent”. All patients indicated that they would recommend the program to other patients with brain tumors. The ReMind-app is the first evidence-based cognitive telerehabilitation program for adult patients with brain tumors and this pilot study suggests that postoperative cognitive rehabilitation via this app is feasible. Based on patients’ feedback, we have expanded the retraining with more difficult exercises. We will evaluate the efficacy of ReMind in an RCT.",
keywords = "CARE, CLINICAL-TRIALS, CONTROLLED-TRIAL, CRITERIA, Cognitive rehabilitation, DEFICITS, DEPRESSION SCALE, Glioma, HOSPITAL ANXIETY, LOW-GRADE GLIOMA, Meningioma, Neurosurgery, REHABILITATION PROGRAM, Telerehabilitation, eHealth",
author = "{van der Linden}, S.D. and M.M. Sitskoorn and G.J.M. Rutten and K. Gehring",
year = "2018",
doi = "10.1007/s11060-017-2738-8",
language = "English",
volume = "137",
pages = "523--532",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Feasibility of the evidence-based cognitive telerehabilitation program ReMind for patients with primary brain tumors. / van der Linden, S.D.; Sitskoorn, M.M.; Rutten, G.J.M.; Gehring, K.

In: Journal of Neuro-Oncology, Vol. 137, No. 3, 2018, p. 523-532.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Feasibility of the evidence-based cognitive telerehabilitation program ReMind for patients with primary brain tumors

AU - van der Linden, S.D.

AU - Sitskoorn, M.M.

AU - Rutten, G.J.M.

AU - Gehring, K.

PY - 2018

Y1 - 2018

N2 - Many patients with primary brain tumors experience cognitive deficits. Cognitive rehabilitation programs focus on alleviating these deficits, but availability of such programs is limited. Our large randomized controlled trial (RCT) demonstrated positive effects of the cognitive rehabilitation program developed by our group. We converted the program into the iPad-based cognitive rehabilitation program ReMind, to increase its accessibility. The app incorporates psychoeducation, strategy training and retraining. This pilot study in patients with primary brain tumors evaluates the feasibility of the use of the ReMind-app in a clinical (research) setting in terms of accrual, attrition, adherence and patient satisfaction. The intervention commenced 3 months after resective surgery and patients were advised to spend 3 h per week on the program for 10 weeks. Of 28 eligible patients, 15 patients with presumed low-grade glioma or meningioma provided informed consent. Most important reason for decline was that patients (7) experienced no cognitive complaints. Participants completed on average 71% of the strategy training and 76% of the retraining. Some patients evaluated the retraining as too easy. Overall, 85% of the patients evaluated the intervention as “good” or “excellent”. All patients indicated that they would recommend the program to other patients with brain tumors. The ReMind-app is the first evidence-based cognitive telerehabilitation program for adult patients with brain tumors and this pilot study suggests that postoperative cognitive rehabilitation via this app is feasible. Based on patients’ feedback, we have expanded the retraining with more difficult exercises. We will evaluate the efficacy of ReMind in an RCT.

AB - Many patients with primary brain tumors experience cognitive deficits. Cognitive rehabilitation programs focus on alleviating these deficits, but availability of such programs is limited. Our large randomized controlled trial (RCT) demonstrated positive effects of the cognitive rehabilitation program developed by our group. We converted the program into the iPad-based cognitive rehabilitation program ReMind, to increase its accessibility. The app incorporates psychoeducation, strategy training and retraining. This pilot study in patients with primary brain tumors evaluates the feasibility of the use of the ReMind-app in a clinical (research) setting in terms of accrual, attrition, adherence and patient satisfaction. The intervention commenced 3 months after resective surgery and patients were advised to spend 3 h per week on the program for 10 weeks. Of 28 eligible patients, 15 patients with presumed low-grade glioma or meningioma provided informed consent. Most important reason for decline was that patients (7) experienced no cognitive complaints. Participants completed on average 71% of the strategy training and 76% of the retraining. Some patients evaluated the retraining as too easy. Overall, 85% of the patients evaluated the intervention as “good” or “excellent”. All patients indicated that they would recommend the program to other patients with brain tumors. The ReMind-app is the first evidence-based cognitive telerehabilitation program for adult patients with brain tumors and this pilot study suggests that postoperative cognitive rehabilitation via this app is feasible. Based on patients’ feedback, we have expanded the retraining with more difficult exercises. We will evaluate the efficacy of ReMind in an RCT.

KW - CARE

KW - CLINICAL-TRIALS

KW - CONTROLLED-TRIAL

KW - CRITERIA

KW - Cognitive rehabilitation

KW - DEFICITS

KW - DEPRESSION SCALE

KW - Glioma

KW - HOSPITAL ANXIETY

KW - LOW-GRADE GLIOMA

KW - Meningioma

KW - Neurosurgery

KW - REHABILITATION PROGRAM

KW - Telerehabilitation

KW - eHealth

U2 - 10.1007/s11060-017-2738-8

DO - 10.1007/s11060-017-2738-8

M3 - Article

VL - 137

SP - 523

EP - 532

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -